Nelfinavir

• 

  Subject Areas on Research

  • Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. 
  • Differences in durability of treatment with initial PI-based regimens. 
  • Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 
  • Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. 
  • Promoter polymorphisms and allelic imbalance in ABCB1 expression. 
  • The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation. 
  • Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.